BACE1 and Alzheimer disease: Disease modifying targets to AD are currently attractive, and include targets involved on the Aβ-plaques and NFT’s production, such as the inhibition of BACE1; increase synaptic signaling through the inhibition of AChE; reduction or prevention of oxidative stress and neuroinflammation.